Trials / Completed
CompletedNCT05378360
DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities
A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708 for Treating Rash Acneiform
Detailed description
All the patients had Grade ≥2 ERSEs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) v. 5.0
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DWP708 | Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days |
Timeline
- Start date
- 2022-05-02
- Primary completion
- 2023-12-05
- Completion
- 2023-12-28
- First posted
- 2022-05-18
- Last updated
- 2024-04-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05378360. Inclusion in this directory is not an endorsement.